An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1 chieve study

Abstract Aim The aim of A1 chieve was to remedy the deficit of data on the efficacy and safety of insulin analogues in routine clinical care in less well-resourced/newly developed countries. Methods A non-interventional, 6-month, observational study of 66,726 people with type 2 diabetes, both insuli...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2011, Vol.94 (3), p.352-363
Main Authors: Home, Philip, Naggar, Nabil El, Khamseh, Mohammed, Gonzalez-Galvez, Guillermo, Shen, Chunduo, Chakkarwar, Praful, Wenying, Yang
Format: Article
Language:English
Subjects:
Endocrinology & Metabolism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aim The aim of A1 chieve was to remedy the deficit of data on the efficacy and safety of insulin analogues in routine clinical care in less well-resourced/newly developed countries. Methods A non-interventional, 6-month, observational study of 66,726 people with type 2 diabetes, both insulin users and non-insulin users, started on insulin detemir, insulin aspart or biphasic insulin aspart in 28 countries across four continents. Results Baseline HbA1c (±SD) was poor: 9.5 ± 1.8%. At 6 months, improvement was −2.1 ± 1.7% in the entire cohort, and −2.2 ± 1.7% and −1.8 ± 1.7% for prior non-insulin users and insulin users. All three analogue therapies gave similar results, again independently of prior insulin use, but also from seven pre-specified country groupings. Overall, hypoglycaemia did not increase in those new to insulin, and fell in those switching insulins. There was no change in body weight (−0.1 ± 3.7 kg), while lipid profile and systolic blood pressure (−6.3 ± 17.1 mmHg) were improved. Conclusions Beginning insulin analogue therapy in people with type 2 diabetes and poor blood glucose control is associated with marked improvements in diverse aspects of vascular risk factor profile without evidence of clinically significant safety or tolerability problems.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2011.10.021